Bloomberg Law
Free Newsletter Sign Up
Login
BROWSE
Bloomberg Law
Welcome
Login
Advanced Search Go
Free Newsletter Sign Up

Endo’s Patent Loss Over Blood Pressure Drug Adds to Its Troubles

Aug. 31, 2021, 6:29 PM

Endo International Plc’s loss in a patent fight over its bestselling blood pressure drug comes at a tough time for the company, as it grapples with opioid lawsuits and weighs a debt restructuring.

Endo’s Par Pharmaceutical lost a trial court ruling Tuesday in its bid to stop Eagle Pharmaceuticals Inc. from selling a generic version of Vasostrict, used to treat low blood pressure. Eagle’s version of the drug won’t infringe two Par patents, U.S. District Judge Colm Connolly in Wilmington, Delaware, said in his opinion, after a three-day trial without a jury in July.

Looming generic drug competition ...